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ABSTRACT
Corticosteroids are used widely to treat many types of disease. In general, these drugs 
are considered safe for the liver; however, recent reports have demonstrated that high-
dose methylprednisolone (MT) may cause severe liver injury. Here, we report a case 
of a 24-year-old female who was given pulsed MT therapy for multiple sclerosis. MT 
induced icteric hepatitis and impaired liver synthetic function. Hepatotoxicity devel-
oped several weeks after drug exposure, and the causal association with MT was con-
firmed by unintentional rechallenge test. A brief review of the literature on corticos-
teroid-induced hepatotoxicity is presented.
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1. Introduction
Adverse drug reactions are frequent and remain 
underestimated causes of acute liver injury that 
sometimes lead to liver failure, requiring liver 
transplantation. 
High-dose intravenous glucocorticosteroid treatment 
is one of the most efficient therapeutic options for 
severe exacerbations of many autoimmune diseases. A 
review of the literature shows that corticosteroids are 
not entirely safe for the liver and have been occasionally 
linked to severe hepatotoxicity (1-3). We present a case 
of a 24-year-old woman who was treated with pulsed 
methylprednisolone (MT) for multiple sclerosis. MT 
induced serious liver injury, developing as icteric 
acute hepatitis with impaired prothrombin synthesis. 
Hepatotoxicity with prolonged latency appeared after 
the second MT pulse, and the causal relationship between 
MT and liver injury was confirmed by unintentional 
rechallenge test.
2. Case Report
A 24-year-old woman with a 3-year history of multiple 
sclerosis and a primary diagnosis of retrobulbar optic 
neuritis was referred to our department due to severe 
acute hepatitis. Three months earlier, she was admitted 
to the neurology department due to exacerbation of 
multiple sclerosis. Neurological treatment began with Hepat Mon. 2011;11(8):656-661
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a 6-day course (0.5 g/d) of high-dose intravenous MT, 
resulting in full recovery of her left arm function. Routine 
laboratory examinations showed normal liver tests and 
no autoantibodies in the peripheral blood. 
The patient was subsequently switched to beta-1b 
interferon (Betaferon) treatment and received 2 doses 
of this drug without any immediate or delayed adverse 
reactions. After 6 weeks, she developed a subsequent 
flare of MS, presenting as left-sided limb paralysis. A 
high-dose intravenous MT pulse (total dose 3.0 g) and 
2 injections of Betaferon were given, effecting nearly a 
full recovery. Four weeks after the MT pulse and 1 week 
after her last Betaferon dose, the patient developed 
jaundice with elevated serum levels of aspartate 
aminotransferase (AST) 900 IU/L (n: 10-31 IU/L), serum 
alanine aminotransferase (ALT) l740 IU/L (n: 9-34 IU/L), 
serum alkaline phosphatase 186 IU/L (n: 38-126 IU/L), and 
serum GGTP 50 IU/L (n: -38 IU/L). The serum bilirubin level 
was 17.9 mg/dL (n: 0.3-1.2 mg/dL), the direct bilirubin was 
16.1 mg/dL, and the prothrombin index was 35.1% (INR 
2.52). The serum AFP level was 17.18 ng/mL (n: < 5 ng/mL). 
The patient had no history of hepatic disease and denied 
any use of alcohol. In the previous 6 months, the patient 
took acetaminophen (used only in a single dose before 
each Betaferon injection) and oral contraception, which 
was stopped immediately before the second MT pulse. 
Serological tests for hepatitis B (including antibodies 
to HBc), hepatitis C, hepatitis A, and infection with 
cytomegalovirus (CMV) were negative. Smooth muscle 
antibodies (SMA) were found in high titers (> 1:320), and 
autoantibodies against mitochondria and nuclei were 
undetected by direct immunofluorescence tests. Her 
copper urinary excretion was not elevated. An ultrasound 
abdominal examination showed an intact liver and a 
normal-sized spleen. No liver biopsy was done due to a 
low prothrombin level. With a MELD (model for end-stage 
liver disease) score of 26, the patient was a potential liver 
transplantation candidate. Fortunately, her liver function 
improved spontaneously, and the patient was discharged 
after 3 weeks with normal aminotransferase levels. 
Considering the potential hepatotoxicity of interferons, 
we cautiously suspected the Betaferon of inducing 
liver injury. Three months later, the patient developed 
a consecutive flare of multiple sclerosis, for which she 
received a 6-day intravenous MT pulse (total dose 3.0 g) 
without Betaferon. Her neurological symptoms resolved, 
but 4 weeks later, she was readmitted to our department 
with symptoms of acute hepatitis. The serum level of AST 
was 1488 IU/L, ALT was 1129 IU/L, alkaline phosphatase was 
164 IU/L, GGTP was 168 IU/L, prothrombin index was 47% 
(INR 1.71), and serum bilirubin was 7.3 mg/dL. No drugs, 
as before, were used to treat the liver disease, and after 
several weeks, aminotransferases and bilirubin reached 
reference levels.
3. Discussion
We report two serious liver injuries that were related 
to pulsed MT treatment. The diagnosis was confirmed 
by the dechallenge-rechallenge relationship between 
drug administration and hepatitis. Based on a literature 
review, we identified 12 case reports of corticosteroid-
induced hepatotoxicity (Table). The clinical course of liver 
injury varied from asymptomatic hypertransaminasemia 
to fulminant hepatic failure (3 deaths). In vivo liver 
histopathology was performed in only 8 cases, showing 
a large spectrum of lesions. Fernandez et al. reported 
recurrent acute hepatitis that was characterized by 
necrosis on histopathological examination, related to 
intravenous MT that was given on 3 occasions for the 
management of relapsing multiple sclerosis (4). Loraschi 
et al. reported 2 cases of liver damage that was related 
to high-dose MT therapy for demyelinating disease 
(5). The first patient, a 33-year-old man, developed a 
histologically recognized acute steatohepatitis 5 weeks 
after last exposure to MT. The second patient, a 27-year-
old woman, presented with moderate and asymptomatic 
augmentation of liver enzymes 6 days after withdrawal 
of MT. Hypersensitivity reactions were not observed 
in any patient. Despite their anti-inflammatory and 
antiallergic properties, corticosteroids also trigger 
immunoallergic liver injuries. Das et al. reported 
recurrent liver injuries that occurred 6 weeks and 3 weeks 
following the second and third course of intravenous 
MT, respectively, for multiple sclerosis (6). Liver biopsy 
showed lobular, primarily perivenular, infiltration with 
activated lymphocytes, eosinophils, and plasma cells. 
Moreover, Japanese authors reported the occurrence of 
autoimmune hepatitis, confirmed by liver histology, in a 
patient with multiple sclerosis who was treated with MP 
pulses (7). In their opinion, autoimmune hepatitis was a 
consquence of an immune rebound phenomenon after 
pulsed MP.
The mechanisms of corticosteroid-induced liver 
injury are unclear and only occasionally are related to 
reactivation of HBV infection or to the excipient of the MT 
preparation (6, 8, 9). Though low doses of corticosteroids 
are considered safe for the liver, chronic administration 
of these drugs may be associated with steatosis or 
steatohepatitis (2, 10). Intrinsic hepatotoxicity of high 
doses of corticosteroids is rather unlikely, as serious 
hepatic injuries that are related to MT occur rarely 
and are unpredictable. The majority of hepatotoxic 
drugs causes idiosyncratic reactions. There are two 
types of idiosyncrasy: immunoallergic and nonallergic 
(metabolic). The essence of an immunoallergic reaction 
is a complex interaction between a parent drug or its 
metabolites with immunologically competent cells, 
leading to necrosis and apoptosis of hepatocytes. 
Released cytokines additionally damage liver cells or 
have immune-modulating effects (11). In metabolic 
idiosyncrasy, the liver injury is caused by aberrant hepatic 
metabolism, leading to overproduction of reactive 
metabolites from a parent compound. In general, 
idiosyncratic drug-induced hepatotoxicity is considered 
to be unpredictable and dose-independent (11); however, Hepat Mon. 2011;11(8):656-661
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it has been suggested that there is dose-dependency for 
drugs that are extensively metabolized in the liver (12). 
MT is metabolized by cytochrome P450 3A4 (CYP3A4), 
and its metabolites undergo renal elimination.
In our patient, we did not observe any systemic 
hypersensitivity symptoms before or during liver 
injury. After two exposures to MT, the hepatitis episodes 
appeared 4 weeks after drug withdrawal. In metabolic 
idiosyncrasy, the latency periods vary considerably 
from days to months, and adverse reactions can occur 
even several weeks after drug discontinuation. Such 
examples are not common but have been reported 
for some antibiotics, such as amoxicillin clavulanate, 
midecamycin, trovafloxacin, and flucloxacilline (13-16). 
The duration of anti-inflammatory effects after a single 
intramuscular injection of 40-80 mg MT ranges from 4 
days to 8 days. Thus, it seems unlikely that chemically 
active metabolites damage hepatocytes 4 weeks after 
drug discontinuation. Rather, this scenario suggests 
a delayed immune response to the metabolite that is 
bound to the host protein and successive presentation 
as a neoantigen to the immune cells following the 
death of hepatocytes. The appearance of SMA following 
exposure to MT might be a feature of the immunological 
response.
4. Conclusion
MT pulses are increasingly used by neurologists, 
rheumatologists, and endocrinologists to treat various 
autoimmune diseases. The general awareness of the 
potential hepatotoxicity of high-dose corticosteroids is 
very low. Corticosteroid-induced liver injury may occur 
as acute hepatitis that develops several weeks after short-
term drug exposure. We therefore feel that MT should be 
placed on the list of hepatotoxic drugs and that patients 
who receive corticosteroid pulses should be screened for 
potential liver injury.
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